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Atopic dermatitis and psoriasis are two chronic skin inﬂammatory diseases that have so far received a greater attention within the
scientiﬁc community through diﬀerent post-genomic approaches; on the contrary, acne, which is undoubtedly one of the most
common skin disorders involving inﬂammatory processes, seems to be still quite neglected under the post-genomic point of view.
In this paper, we will review how post-genomic technologies have provided new fundamental tools for the analysis of these three
conditions and we will cast light on their potential in addressing future research challenges.
1. Skin,OxidativeStress,andLipidPeroxidation
Skin represents the major interface between the body and
the environment; consequently, it is chronically exposed
to the harmful action of many chemical/physical toxicants.
Besides forming a biological barrier to protect internal
organs and systems from the external environment, skin
can also symptomatically reﬂect internal diseases [1]. Both
exogenously and endogenously generated compounds or
their metabolites can directly or indirectly lead to the
generation of a wide variety of reactive oxygen species
(ROS), short-lived compounds that are normal by-products
of aerobic metabolism. If generated in excess, ROS can
quickly overwhelm the skin antioxidant defence systems.
Such an imbalance in the production/inactivation of ROS
is generally known as “oxidative stress” and is one of the
causes for the damage of biological molecules (such as
DNA, carbohydrates, lipids, and proteins) and the release of
inﬂammatory cytokines [2, 3].
Lipid peroxidation (LPO) is basically deleterious because
it leads to a diﬀuse spread of free radical reactions [4].
Membrane lipids, and mainly phospholipids containing
polyunsaturated fatty acids (PUFAs) [5], are particularly
prone to peroxidation because of their association within the
cell membrane with nonenzymatic and enzymatic systems
generating pro-oxidative free radical species. As a conse-
quence, under various conditions and pathological states,
an oxidative cascade may be generated that can, in turn,
induce cytotoxicity and apoptosis and may have a signiﬁcant
role in inﬂammation enhancing the release of cytokines and
modifying lipoproteins to proinﬂammatory forms [5, 6].
LPO products readily react with proteins, sugars, and
DNA [7]. There are numerous reports indicating that end
products of LPO, such as malondialdehyde (MDA), 4-
hydroxy-2-nonenal (4-HNE), and 4-hydroxy-2-hexanal (4-
HEE) can damage proteins by reacting with various amino
acids both in vivo and in vitro [4]. At the same time,
it has been shown over recent years that LPO products
at low concentrations activate the cellular cytoprotective
signaling pathways and increase antioxidant capacity [8].
The understanding of the eﬀects of oxidative stress and LPO
productsinsignaltransductionrepresentstheparadigmshift
in the concept of oxidative stress, for which now diﬀerent
deﬁnitions exist. One of them is a notion that stress is a
signal and oxidative stress is a signal which induces oxidative
reaction and/or aﬀects redox balance, resulting in either
stimulation of defence capacity or induction of deleterious
damage. As Selye, a pioneer in the ﬁeld of biological stress,
observedfordiverseagentsandcoinedtheterm[9],oxidative
stress and LPO may turn to either positive stimulus, eustress,
or deleterious insult, distress [7].
Oxidative stress has been already indicated as the
underlying mechanism of various diseases, and compelling
evidences have been produced to demonstrate a link between2 Mediators of Inﬂammation
oxidative stress, especially LPO, and various inﬂammatory
dermatologic conditions such as atopic dermatitis (AD)
[10] and psoriasis [11]. Consistent with this notion, several
groups have shown increased levels of LPO products in
biological ﬂuids and tissues from diﬀerent pathological
conditions. Nonetheless, whether LPO is the cause or the
consequence of a disease condition is still an open question
that needs to be addressed [7]. The fact that ROS, at
moderate concentrations, can act as second messengers in
the induction of biological responses and are speciﬁcally
required as mediators/transduction molecules for signalling
provides support to a correlation between oxidative stress
and inﬂammation. On the other hand, an overproduction of
ROS may completely imbalance the redox-homeostasis and
irreversibly damage cell components, eventually leading to
apoptosis. Oxidative stress, driving the production of lipid
peroxides and their oxidation products, may thus be critical
for the development of skin inﬂammatory diseases because
an increased LPO may evoke immune responses, cause an
excessive cytokine release, activate gene expression, aﬀect
cell proliferation, and induce apoptosis. Strengthening this
hypothesis, it has recently been shown that the peroxisome
proliferator-activated receptors (PPARs, whose natural lig-
ands are PUFAs and their oxidation metabolites) may drive
the development of psoriasis and acne [12].
2. Post-Genomics
The comprehension of skin diseases has advanced rapidly in
the last several years, as dermatologic science is beginning to
unravel the pathophysiology behind such diverse conditions.
T h o u g hi nv i t r om a r k e r so fL P Oh a v eb e e nm a d ea v a i l a b l e ,
their value can be limited by the fact that assays may lack
sensitivity or require invasive methods to collect samples.
Additionally, the choice among in vivo generated LPO
products may pose relevant limits to the analysis, making
the identiﬁcation and quantiﬁcation of these products more
diﬃcult. This is because such a determination in biological
ﬂuids and tissues takes into account and reﬂects the balance
among formation, metabolism, clearance, and excretion of
various compounds [4, 7].
The usefulness of biomarkers for the characterization of
skin diseases is undoubted; nonetheless, their contribution
could be read only in a very speciﬁc fashion. In fact, as seen,
oxidative imbalances might aﬀect many cellular functions,
producing a complex scenario whose evaluation could be
of greater interest and lead to a more detailed picture of a
disease. As tools for systems biology are becoming increas-
ingly available, it will be possible to analyse the generation,
metabolism, and partitioning of LPO products together with
their associated eﬀects on cell molecular targets as well as to
establishacorrelationbetweenalterationsofspeciﬁcproteins
and a speciﬁc inﬂammatory skin disease. Eﬀorts are already
being made to apply post-genomic technologies aiming
at a comprehensive characterization of skin inﬂammatory
diseases through extensive mapping of cell components at
the levels of the transcriptome and the proteome. This will
likely ultimately lead to a picture of the signalling networks
that mediate the biological eﬀects of LPO [5].
In February 2001, the entire sequence of the human
genome was ﬁrst published [13, 14]. Once identiﬁed, the
complete coding region of a gene is readily obtained. DNA
microarrays, generating a high-throughput transcriptional
proﬁle of cells, can quantitatively analyze thousands of genes
simultaneously and allow a global characterization of a
speciﬁc molecular process. A growing body of evidences
indicates that protein expression changes are important in
skin diseases, and several large-scale expression proﬁlings
describing diﬀerential gene expression in skin diseases have
been published. Nonetheless, they cannot provide informa-
tion concerning the translational regulation of expression
or posttranslational modiﬁcations (PTMs) of proteins, or
qualitative and quantitative changes in the steady-state
levels of proteins in biological systems. Investigators should
then focus their attention on proteins, the results of gene
expression, to determine how proteins might be responsible
for the normal functioning cells. Only then the true role of a
gene in the disease process can be understood. Proteomics
is indeed the answer to these questions, as it can proﬁle
in a biological system the entire repertoire of proteins,
including their isoforms and molecular species generated
by PTMs (such as phosphorylation, glycosylation, oxidation,
cleavage, and many others). The proteomic approach has
been widely and extensively applied to the study of many
human conditions whereas it is still in its infancy in
cutaneous biology. However, the use of proteomics has the
potential to elucidate which role speciﬁc proteins play in
inﬂammatory skin manifestations and possibly speed up the
identiﬁcation of therapeutically relevant targets.
Being proteins involved in complex protein networks,
signiﬁcant challenges must be faced in the study of protein
functions and interaction maps. Functional proteomics
and systems biology may hence provide new insights to
gain a deeper understanding of cell systems and pathway
properties also in skin diseases [15, 16]. Typically, proteins
seek out other proteins, interaction partners, to complete
their function(s). These partners may serve simply to
hold proteins in particular orientation or involve structural
modiﬁcations conferring new activities. By delineating these
networks, scientists can gain an understanding of the role
each individual protein plays in biochemical pathways, and
thus a disease process. This knowledge can then be used
for a focused approach to discover chemicals that might be
eﬀective in a disease state [17]( Figure 1).
Proteomics and transcriptomics have been applied to
the study of several skin conditions, such as scleroderma,
eczema, burn wounds, irritation induced by sodium lauryl
sulphate, or cell responses to inﬂammatory interleukins.
Several post-genomic studies have been dedicated so far to
the study of two skin inﬂammatory diseases, that is, AD
and psoriasis whereas acne, which is undoubtedly one of
the most common skin conditions involving inﬂammatory
processes, seems to be still quite neglected under the post-
genomic point of view. In the present work, we will review
how post-genomic technologies have been used and which is
theirpotentialinaddressingfuturechallengesabletoprovide
vital insights on the pathogenic mechanisms of these three
conditions.Mediators of Inﬂammation 3
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Figure 1: The integration of diﬀerent post-genomic technologies
for the study of skin inﬂammatory diseases.
3. Psoriasis
Psoriasis vulgaris is among the most prevalent chronic
inﬂammatory skin diseases. Typically, the disease manifests
as inﬂamed plaques prevalently in scalp, elbows, and knees.
The plaques are characterized by erythema, induration,
and silvery scaling. Hyperproliferative keratinocytes lack
terminal diﬀerentiation, as seen by the formation of hyper-
parakeratotic stratum corneum [18]. In the typical picture
of psoriatic skin, disregulated fatty acid metabolism, ROS
generation, cytokine release, and LPO have all been reported
[2].
Acombinationofgenesisundoubtedlyrequiredtoreveal
the psoriasis phenotype after exposure to an environmental
trigger, such as streptococcal pharyngitis or tonsillitis [19].
The elucidation of genes and gene products in psoriasis is
of vital importance if targeted therapies are to be designed
that may cure or possibly prevent the disease. Perhaps the
most important consequence of identifying psoriasis genes is
the ability to develop a transgenic animal model for psoriasis
that will allow rapid and economic screening of potential
therapeutic agents [20]. No such model exists, the nearest
being an immunodeﬁcient mouse xenografted with biopsies
of human psoriasis [21].
Global comprehensive studies on gene expression in
psoriasis have been carried out to elucidate the mechanisms
of the disease. Particularly, the transcriptome (analysis
of RNA expression proﬁling) has been investigated using
diﬀerent technological platforms: Gene Chips microarray
[22–24], cDNA array [25], and Serial Analysis of Gene
Expression (SAGE) [26]. These studies consistently found
diﬀerential expression of genes related to cell regeneration,
hyperkeratosis, metabolic functions, immune responses, and
inﬂammation in lesional psoriatic skin and, altogether,
provided a large number of novel gene markers. However, a
detailed correlation between gene expression proﬁles of pso-
riatic skin and local and overall clinical parameters, as well as
ananalysisoftheinﬂuenceofthebiopsylocationonthegene
expressionproﬁleinpsoriaticskin,wasnotreporteduntilthe
workby Quekenborn-Trinquet et al. [25]. In this work, using
gene expression proﬁles of involved psoriatic skin through
cDNA array and kinetically monitored reverse transcriptase-
initiated polymerase chain reaction (kRT-PCR), authors
compared gene expression proﬁles of plaque psoriasis at
diﬀerent anatomical sites for both symmetrical and asym-
metrical diseases. Gene clustering failed to highlight any
correlation with family history of psoriasis, age at onset,
association with arthritis, and plaque location and type.
Nonetheless, expression proﬁle analysis highlighted distinct
patternsaccordingtobothglobal(PsoriasisAreaandSeverity
Index) and local (erythema, desquamation, and plaque
elevation) clinical severity. Three novel psoriasis markers
were identiﬁed in the work, namely SPRR2C (marker of
abnormal keratinocyte diﬀerentiation), MX2 (transcription
factor involved in mediating the proinﬂammatory eﬀects
of IFN-γ), and CYC1 (belonging to cytochrome-c family,
indicates the high energetic request of highly proliferating
epidermis of psoriatic lesions, also pointing out a transcrip-
tional deregulation of proapoptotic factors) [25].
To identify diﬀerentially expressed genes which play
causal roles in pathogenesis and maintenance of psoriasis,
the BodyMap database combined with an RT-PCR-based
ampliﬁed fragment length polymorphism (iAFLP) analysis
was used by Itoh et al. 241 genes were found to be
diﬀerentially expressed only in involved psoriatic skin, and
sevengenesshowedhighexpressionlevelsonlyinuninvolved
psoriatic lesions. These seven genes, which were reported to
berelatedtoapoptosisorantiproliferation,mighthavecausal
roles in the pathophysiology of psoriasis [27].
A genomic approach was also undertaken by Lew et al.
in order to discriminate the genomic signature of large
plaque (Western) and small plaque (Asian) psoriasis [28].
However, authors led to the conclusions that these two
manifestations share a similar genomic signature though a
potential diﬀerence in IL-18 exists. Additionally, in the paper
by Dezso et al. a computational methodology capable of
predicting key regulatory genes and proteins in psoriasis is
described. Using a dedicated algorithm and a global database
of protein interactions, many biological targets of psoriasis
were conﬁrmed while several new ones were suggested
[29].
Functional proteomics and systems biology are two
emerging concepts that highlight the functional analysis
of proteins and the networks they belong to. Applied to
dermatological sciences, they can help researchers to get a
better and clearer understanding of many skin diseases [15].
A pioneer proteomic approach to study psoriasis was
carriedoutbyCelisetal.,whoﬁrstestablisheda2Dreference
map for normal noncultured epidermal keratinocytes [30]
andthenrevealedsixlow-molecular-weightproteinsstrongly
upregulated in psoriatic skin that were proven to be partially
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and B and cystatin A, while two of them were cloned, sub-
sequently sequenced, and identiﬁed as “psoriasin” [32]a n d
psoriasis-associated fatty acid-binding protein (PA-FABP)
[33], pointing out a disregulated fatty acid metabolism in
psoriatic cells. This observation was also in line with reports
showing that the skin of psoriatic patients contains increased
totallipids,phospholipidsaswellasfreearachidonicacidand
derived products.
The genetic background of psoriasis appears to be
complex and whether diﬀerent psoriasis phenotypes are
associated with distinct genotypes is still unclear. Current
research suggests that there is both clinical and genetic
evidence for heterogeneity in psoriasis, but whether pso-
riasis actually consists of diﬀerent diseases with distinct
etiologic backgrounds has yet to be resolved. There is
considerable overlap in phenotype expression and a single
individual can display diﬀerent psoriasis manifestations over
time. Carl´ en et al. tried to identify diﬀerences between
acute guttate and chronic plaque psoriasis at the protein
level [34] using classical 2-DE plus Matrix-Assisted Laser
Desorption/Ionization-Time Of Flight (MALDI-TOF) or
Liquid Chromatography coupled with Mass Spectrometry
(LC-MS/MS) for protein identiﬁcation. The two phenotypes
were clearly distinguishable and, interestingly, authors found
a trend in which guttate psoriasis lesions clustered closer to
eczema than to chronic plaque psoriasis lesions, indicating
that the duration of the inﬂammatory reaction may aﬀect
clustering.Thisobservationunderscoredthedynamicnature
of skin inﬂammation in line with reports from AD, where
theinﬂammatoryandcytokine networksundergosigniﬁcant
changes over time [35, 36].
Intrinsic limitations characterize 2-DE analysis. First, 2-
DE is not sensitive enough to detect proteins at pico-femto-
molar levels, highly acidic or basic proteins, some membrane
hydrophobic proteins, or very large (>250kDa) and very
small (<8kDa) proteins. For all of these reasons, alternative
approaches have been developed based on aﬃnity-based
protein puriﬁcation strategies, variants of 2D-LC, LC cou-
pled with capillary electrophoresis, and multidimensional
LC in combination with MS [15]. For instance, Cowen
et al. [37] undertook as MS analysis of serum samples
from psoriatic patients (serum proteomics) to determine
the proteomic signature of the disease. The rationale of
the study relied on the fact that proteins associated with
inﬂammatory processes in the skin are likely released into
the extracellular space, entering the lymphatic vessels and,
ultimately, the blood. Endothelial cells in skin also produce a
varietyofcytokineschemokinesandadhesionmoleculesthat
arereleaseddirectlyintothecirculationduringinﬂammatory
skin reactions. Both these processes may be expected to lead
to quantitative as well as qualitative changes in the serum
protein proﬁle. Although facing the complexity of the serum
proteome and the limitations of current protein technology,
the work by Cowen et al. was an interesting pilot ‘proof
of concept’ study. This also because, due to the visibility
and relatively easy access to aﬀected tissues in cutaneous
diseases, the combination of serum and tissue proteomic
techniques might allow for potential correlation, validation,
and reproducibility studies.
A similar approach, based on a combination of abundant
protein depletion and multilectin aﬃnity chromatography
(M-LAC) combined with nanoﬂow liquid chromatogra-
phy coupled with mass spectrometry (nano-LC-MS/MS),
allowed Plavina et al. [38] to indicate galectin-3 binding
protein (G3BP) as a protein marker for psoriasis.
Although the need for biomarker discovery for psoriasis
is not pressing, because it is easily diagnosed from patients’
symptoms, a better understanding of the disease pathogene-
sis is certainly needed to predict its severity, to identify new
therapeutic agents, and for prognostic purposes. To address
some of these issues, Plavina et al. [39] furthered their
investigations on plasma from psoriatic patients using the
approach described above to enrich glycoproteins together
with a second method, based on ultracentrifugation and
analysis of peptides by nano-LC-MS/MS with high accuracy
Fourier transform, to analyze the low-molecular-weight
(LMW) peptidome. The fruitful combination of proteomics
andpeptidomicsallowedauthorstodetectincreasedconcen-
trations of cytoskeletal proteins and their fragments in pso-
riatic plasma, suggesting disease-related cell leakage of these
proteins and their increased proteolysis. Moreover, authors
found increased concentrations of two proteins known to
play a role in a genetic predisposition to psoriasis and in
the diﬀerentiation of keratinocytes: calgranulins A and B.
On this basis, it was hypothesized that the overproduction of
calgranulins may alter calcium homeostasis in the epidermis
andleadtoalteredrelocalizationofcytoskeletoncomponents
and their abnormal proteolysis, as well as to immune
responses against circulating cytoskeletal proteins. Another
striking ﬁnding was a decrease in ﬁbrinogen fragments,
suggesting a possible involvement in autoimmunity and
inﬂammation and letting authors hypothesize a link between
altered proteolysis of ﬁbrinogen due to changes in its PTM
and the development of psoriatic arthritis.
4.AtopicDermatitis
AD is a chronic relapsing inﬂammatory skin disease fre-
quently associated with skin infections and impaired skin
barrier function [40]. The disease can seriously compromise
the quality of life as it is characterized by the distribution of
eczematous skin lesions. AD typically reveals licheniﬁcation,
pruritic excoriations, and dry skin with a variety of patho-
physiologic manifestations. The extrinsic type of AD (ADe)
is associated with IgE-mediated sensitization and accounts
for 70%–80% AD cases, while the intrinsic type (ADi) does
not involve IgE and accounts for 20%–30% of AD cases. It
is generally recognized that a combination of environmental
f a c t o r ss u c ha sa l l e r g e n sa n db a c t e r i a li n f e c t i o n ,a sw e l la s
genetic factors, is the principal inducers of the multiple
immunologic and inﬂammatory responses seen in AD
patients [41]. An impaired oxidative status has been already
associated to AD, and systemic alterations in antioxidant
patterns have been found in involved skin of AD patients
as well as in uninvolved nonlesioned skin as an adaptive
response to chronic inﬂammation of the epidermis [2].
Filament aggregating protein (ﬁlaggrin, FLG) is a key
protein that plays an important role in the formation ofMediators of Inﬂammation 5
the corniﬁed cell envelope (CCE), which is critical for an
eﬀective skin barrier [42]. Genetic studies have shown that
loss-of-function (null) mutations in the gene encoding FLG
result in impaired skin barrier in AD [43–45]. Howell et al.
demonstrated that FLG gene expression and FLG protein
are decreased in the skin of patients with AD and indicated
that this deﬁciency is caused, in part, by the overexpression
of TH2 cytokines IL-4 and IL-13 that downregulate FLG
expression during keratinocyte diﬀerentiation. This implies
that many patients with AD acquire the FLG deﬁciency
with subsequent barrier disruption as the result of the
local inﬂammatory immune response [46]. However, FLG
mutations alone do not provoke AD because the mutations
can be observed only in a group of patients from certain
ethnic groups (as many as 20% in all patients with AD and
50% in patients with severe AD) [47]. Similar mutations
were also reported in approximately 9% of the European
population without concomitant inﬂammation [43].
In 2009, Guttman-Yassky et al. [47]r e p o r t e dac o m -
prehensive gene (mRNA) expression proﬁle of AD and
psoriasis by using normal skin as a reference. Although both
the diseases share epidermal hyperplasia and regenerative
epidermal growth, terminal diﬀerentiation was found to be
accelerated in psoriasis but broadly suppressed or defective
in AD. Authors found that psoriasis and AD can be correctly
discriminated on the basis of diﬀerences in expression of
terminal diﬀerentiation genes, much like disease distinc-
tions made on the basis of immune-response phenotypes
(“immune-signature” based on a set of 10 immune related
genes).
Though the incidence of AD is rapidly increasing, a
treatment oﬀering quick relief of symptoms still remains
to be developed. Various methodological approaches along
with the new technologies can be fruitfully combined to this
aim, especially DNA microarray and interactomic tools [41].
With DNA microarray, although obtaining a great number
of disregulated genes in a disease, it is very diﬃcult to choose
the most important genes and it is hard to explain the
meaning of encoded proteins. In this regard, interactomic
tools may help ﬁnd the core proteins among the detected
candidate genes. Since the next step of functional studies is
a time- and cost-consuming process, the number of target
proteins must be limited; hence, to make the right choice,
computational prediction on the basis of microarray results
could be critical to piece together such a complete puzzle
[48]. In light of this, L¨ u et al. [48] attempted to proﬁle gene
alterations of AD keratinocytes and corroborated microarray
results with protein-protein interaction (PPI) mapping to
predict the genes related with AD functioning as interaction
hubs.InpunchbiopsiesfromADipatients,theyidentiﬁed25
predictedhubgenesandtwoimportant candidatebiomarker
genes (MMP1 and MMP10) signiﬁcantly upregulated, both
at the cellular (keratinocyte) level and in serum. In a large
scale DNA chip array, the same group focused on ADe and
used205candidategenestocarryoutPPIpredictionthrough
bioinformatic analysis. The identiﬁed hub genes were mainly
involved in ﬁve functional classes: ECM and cell adhesion,
ATP/GTP binding, immune response, proteolytic enzymes,
and structural genes [48].
Gene chip arrays were used in AD with various purposes,
including:
(i) the identiﬁcation of gene expression speciﬁc to active
atopic skin lesions [49] such as the abnormal epider-
mal diﬀerentiation and defective defences found by
Sugiura et al. as key abnormalities in AD [50];
(ii) the identiﬁcation of gene transcription changes
associated with early AD inﬂammation as potential
disease control targets [51];
(iii) the pattern comparison between gene expression in
AD versus psoriasis in an eﬀort to identify potentially
new gene targets that may be useful in the diagnosis
and treatment of skin diseases [52];
(iv) the understanding of why patients with AD, but
not psoriasis, frequently suﬀer from serious skin
infections [53].
Both proteomic and gene expression proﬁlings of AD
ﬁbroblasts were carried out by Park et al. They investigated
alterationsinproteinexpressioninprimaryculturedADcells
from ADe and ADi biopsy samples by classical 2-DE and
MALDI-TOF [54] and additionally extended their analysis
with the use of diﬀerent pH gradients [55] to increase the
possibility to detect protein markers. They also reported,
notably, that PTMs of candidate proteins may be relevant in
the development of the disease [54].
Then, Park et al. investigated the protein repertoire
of primary cultured keratinocytes from AD samples and
reported alteration of lipid metabolism-associated proteins
within these cells, providing important clues to explain the
presence of dry skin and pruritus in AD patients, as well as
new insights into the identity of metabolic enzymes involved
in AD pathogenesis [56]. In further works, Park et al. carried
out a cDNA microarray analysis of ﬁbroblasts from ADe and
ADi where they suggested that human dermal ﬁbroblasts
may actively participate in AD disease [57]a n dp r o p o s e d
acetaldehyde dehydrogenase 1 (ALDH1) as a biomarker for
AD disease using proteomic proﬁling of ﬁbroblasts from ADi
and ADe samples [58].
Howell et al. undertook a Diﬀerential In Gel Elec-
trophoresis (DIGE) proteomic approach to investigate the
global eﬀects of IL-4 and IL-13 (which are well known to
play a role in AD) on protein expression in keratinocytes.
Notably, authors identiﬁed factors contributing to the sig-
niﬁcant barrier disruption and antimicrobial peptide (AMP)
deﬁciency observed in the skin of AD patients and identiﬁed
novel targets to enhance keratinocyte diﬀerentiation and
skin innate immune responses in this common skin disease
[59].
Glycoproteome is a major subproteome, since many
clinical biomarkers and therapeutic targets are glycoproteins.
In particular, the glycosylation patterns are inﬂuenced
considerably by the physiological status [60, 61]. In their
work, Kim et al. carried out a diﬀerential glycoprotein
proﬁlingofplasmafromhealthydonorsandADpatientsand
identiﬁed several diﬀerentially expressed proteins suggested
as potential biomarkers in the diagnosis of AD or in tracking
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The goal of the recent pilot study by Broccardo et al.
[63] was to develop an MS-based, noninvasive skin taping
technique to study AD in infants and young children. In
fact, though the disease aﬀects mainly this age group, there
are no skin-based studies on such a population because of
the invasiveness of sampling biopsies. Besides conﬁrming
previous reports on unique proteins identiﬁed in AD
samples, this proof-of-principle pilot study revealed also
newpotentialbiomarkerstoinvestigateADdevelopmentand
persistence.
5.Acne
Aﬀecting millions of people worldwide, acne is the most
common skin inﬂammatory condition. Although an incom-
pletely understood pathogenesis, acne has been linked
to multiple factors such as increased sebum production,
inﬂammation of hair follicles and sebaceous glands, fol-
licular hyperkeratinisation, and colonization by Propioni-
bacterium acnes [78]. Nonetheless, only a minor number
of works based on post-genomic technologies could be
found on acne, highlighting the quite neglected nature of
this disease.
The ﬁrst comparative gene array expression proﬁling
between inﬂammatory acne lesions and normal skin was
carried out by Trivedi et al. in 2006 [79] and showed that
many of the genes whose expression is increased in acne
lesions are involved in inﬂammatory processes, the major
genes including the matrix metalloproteinases MMP-1 and
MMP-3, as well as the pro-inﬂammatory cytokine IL-8
and CXCL-2. This ﬁnding, together with the induction of
several AMPs (e.g., granulysin) and proapoptotic enzymes
(e.g., granzyme B), supported the correlation between
inﬂammatory mediators and the extent to which P. acnes
induce the expression of the AMP β-defensin (now known as
DEFB-4) and IL-8 [80]. Critical questions remain, however,
about the nature of the initiating events in the development
of acne lesions. It is likely that gene expression proﬁles
of inﬂammatory process in the skin are quite similar and
that many of the changes observed in inﬂammatory lesions
are secondary to as yet unidentiﬁed primary pathogenic
events. The challenge lies ahead in identifying these primary
events in acne as well as in other inﬂammatory diseases
[79].
Unlike humans, most animals produce little or no
triglycerides in hair follicles to harbour P. acnes,af a c t
that has encumbered the development of in vivo models.
Althoughgeneticmutantmicewithacne-likeskinshavebeen
used for screening antiacne drugs, the mice generally have
deﬁcits in immune system making them inappropriate to
generate antibodies for developing acne vaccines. Nakatsuji
et al. undertook a bioengineering approach to create a
humanized acne microenvironment where proteomics using
isotope-coded protein label (ICPL) coupled to nano-LC-MS
analysis was carried out to investigate in vivo interactions
among P. acnes, human sebocytes, and host immune cells.
Thirteenproteinswereidentiﬁed,includingsecretedproteins
and cell matrix proteins derived from mouse, human cells,
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Figure 2: Approaches and strategy for the analysis of protein
repertoires.
or P. acnes, indicating the coexistence of protein repertoires
from diﬀerent origins. Altogether, these results may provide
new pharmacological targets for the treatment of acne and a
valuable model for drug screening and vaccine development
[81].
6. Challenges and FutureDirections:
Redox-Proteomics and Immunoproteomics
Proteomicsofskininﬂammatorydiseasesisstillinitsinfancy
and much remains to be done. For instance, the combined
use of 2-DE and Western Blot (immunoproteomics), the
investigation of cell secretomes (secretomics), and the discov-
ery of oxidative PTMs of proteins have so far received little
attention in this ﬁeld of research (Figure 2).
PTMsplaykeyrolesinmanyimportantcellularfunctions
by inﬂuencing protein subcellular localization, protein-
protein interactions, and cellular biological activities. Alto-
gether, PTMs ﬁnely orchestrate regulatory processes as
well as cellular responses upon speciﬁc stress conditions.
If irreversible, PTMs might be associated with permanent
protein loss of function and may lead to the elimina-
tion or to the accumulation of the damaged proteins. If
reversible, particularly at the cysteine residues, PTMs may
have the dual role of protection from irreversible oxidation
and modulation of protein function (redox regulation)
[82].
Relying on both gel-based and gel-free approaches,
several techniques are available and oﬀer tremendous oppor-
tunitiestoanalyzePTMs,helpingintheelucidationofpatho-
physiological mechanisms in diseased or stressed cells. Since
oxidative stress may induce several modiﬁcation on proteins,
the term “redox-proteomics” was coined to describe the
multiple applications of proteomics for the discovery of
oxidative PTMs. Nonetheless, an accurate identiﬁcation of
proteinPTMsinrelationtoskininﬂammatorydiseasesisstill
lacking.Mediators of Inﬂammation 7
Table 1: Oxidative PTMs of proteins and techniques for their study.
oxidative PTM
description
gel-based approaches + MS protein
identiﬁcation gel-free approaches
3-nitroTyrosine WB detection with α-nitroTyr antibodies
[64–68]
4-HNE-adducts WB detection with α-4-HNE antibodies
[64, 69]
LC-ESI-MS/MS, as well as tryptic
digestion, avidin column
enrichment and MS/MS analysis
following
N
-aminooxymethylcarbonylhydro-
D-biotin labeling
[70, 71]
Carbonylation
derivatization of protein carbonyls with
2,4-dinitrophenylhydrazine (DNPH) and
WB detection of the resulting
2,4-dinitrophenylhydrazones (DNP) with
α-DNP antibodies; alternatively,
biotin-hydrazide tagging and avidin-FITC
staining [64, 66, 68, 69, 72, 73]
enrichment strategies with the
hydrazide biotin-streptavidin
methodology or Girard’s P reagent,
coupled with LC-MS/MS and
MALDI-MS/MS [66, 69–71]
Glycosylation
(i) lectin chemistry (due to a diﬀerent
speciﬁcity for certain carbohydrates, the
identiﬁcation of subclasses is allowed) [65]
(i) lectin aﬃnity chromatography to
isolate glycosylated proteins from
complex mixtures prior to MS/MS
[74]
(ii) periodate/Schiﬀ’s base chemistry to
generate a general stain toward
glycoproteins (Pro-Q Emerald staining) [65]
(ii) chemical trapping of
N-glycosylated peptide prior to
LC-MS/MS [74]
(iii) chemoenzymatic or tagging via
substrate strategies for
O-glycolsylated peptided [74]
(iv) COFRADIC [74]
Oxidation of -SH groups
various techniques to reveal speciﬁc -SH
PTMs [66, 68, 73, 75]
(i) oxidation, lack of labelling with speciﬁc
reagents, such as biotinylated
iodoacetamide, and WB detection with
streptavidin
(i) isolation of cysteinyl peptides by
biotinylation of Cys residues and
aﬃnity isolation (ICAT) [74]
(ii) S-glutathionylation, metabolic labelling
of the intracellular glutathione pool with
35S-cysteine while inhibiting protein
synthesis plus nonreducing electrophoresis,
and autoradiography
(ii) S-nytrosilation, modiﬁed biotin
switch method coupled with aﬃnity
isolation [74]
(iii) S-nytrosilation, biotin switch method (iii) COFRADIC [74]
(iv) formation of disulphide bridges,
diagonal 2-DE
(v) sulﬁnic/sulfonic acid: detection through
MS after standard trypsin digestion
Phosphorylation
(i) in gel protein staining with speciﬁc dies
(Pro-Q Diamond) [65, 76]
(i) isolation of phosphopeptides by
immobilized ion chromatography
(IMAC) [74]
(ii) WB with antibodies towards speciﬁc
phosphorylated amino acids
(ii) segregation of phosphopeptides
by strong cation exchange
chromatography or titanium
dioxide [74]8 Mediators of Inﬂammation
Table 1: Continued.
oxidative PTM
description
gel-based approaches + MS protein
identiﬁcation gel-free approaches
(iii) various chemical reactions
aiming at modifying the
phopshorylated peptides prior to
MS/MS [74]
(iv) COFRADIC [74]
multiple PTMs SEMSA during LC-ESI-MS/MS [77]
In Table 1, some of the most commonly investigated
oxidatively induced protein PTMs are reported, together
with the reagents and techniques for their detection. Among
these PTMs, the introduction of carbonyl groups has
probably received the greatest attention within the scientiﬁc
community. Carbonylation of proteins is an irreversible,
easy detectable, and nonenzymatic PTM often accompa-
nied by protein loss of function. For these reasons, it
has been investigated widely in human diseases and it
is universally accepted as a reliable indicator of oxida-
tive stress [83–85]. The levels of protein carbonyls in a
sample and especially the identiﬁcation of target proteins
through 1-DE or 2-DE and WB have been reported in
several organisms and under many pathological conditions,
providing evidences for evolutionarily conserved carbony-
lation patterns [86] and suggesting a role for the regu-
lation of fundamental cellular events, including apoptosis
[87–89].
Despite the insights provided by these studies, only
recently the identiﬁcation of the exact amino acid site and
typeofcarbonylmodiﬁcationhasemerged.Thisinformation
is necessary for a deeper understanding of the oxidative
mechanisms leading to the protein modiﬁcation as well
as for providing information for the assessment of the
functional eﬀects that modiﬁcation of speciﬁc amino acid
sites may have on proteins. Therefore, the continuous
evolution of MS techniques might drive researchers towards
this important goal [90]. As an example, gel-free methods
usingenrichmentofcarbonylatedpeptidesfollowedbydirect
LC-MS/MS analysis have been developed [72]. Interest has
also been dedicated to the identiﬁcation of modiﬁcations
induced by 4-HNE relying on LC-ESI-MS/MS [70], as
well as tryptic digestion, avidin column enrichment of
the modiﬁed peptides, and MS/MS analysis following N
-
aminooxymethylcarbonylhydro-D-biotin labeling [71]
Sulfur-containing amino acids are among the best
susceptible targets of PTMs during oxidative stress [91].
Proteins thiol groups play a fundamental role in numerous
cell processes, and their redox state is involved in both
structure and function of many receptors, enzymes, and
transcription factors. Thiol oxidation often leads to alter-
ationsinconformationandcatalyticactivityofproteins[92];
nonetheless, these events do not necessarily have to be seen
as damaging. If, on the one hand, thiol oxidation could be a
“random” event, on the other, it can be part of ﬁnely tuned
processes that protect proteins from irreversible oxidation
or activate speciﬁc functions related to stress response. The
availability of diﬀerent labelling reagents and electrophoretic
techniques oﬀers researchers important tools to unravel
the importance of thiol oxidation in skin inﬂammatory
diseases.
ROSmayalsobeinvolvedinskinimmunemanifestations
[2, 3] and LPO has been already linked to autoimmune
diseases. Reaction between MDA and endogenous proteins
mightleadtotheircovalentmodiﬁcations,resultinginstruc-
tural changes in the proteins, which might act as neoantigens
inducing an autoimmune response. In fact, signiﬁcantly
increased anti-MDA epitope(s) autoantibodies were found
in patients with systemic diseases, such as scleroderma, sup-
porting the hypothesis that aldehydic degradation products
of LPO may contribute to the autoimmune pathogenesis
[93]. Additionally, some aldehyde modiﬁcations have been
demonstratedtoevokestrongantibodyreactivityalsoagainst
nonmodiﬁed proteins [94]. More generally, free radicals and
aldehydes produced by chronic inﬂammation can induce
a number of alterations, including gene mutations and
PTMs of key proteins, eventually leading to disruption of
cellularprocesses.Drivingtheproductionofα,β-unsaturated
fatty aldehydes including MDA and 4-HNE, LPO can
ultimately result in the production of protein adducts
and in the elicitation of speciﬁc autoantibody formation
[95, 96].
For all of these reasons, understanding how proteins
are actually aﬀected by oxidative stress and inﬂammation
is vital. Proteomics and immunoproteomics, in particular,
might help the elucidation of disease aetiology. In the case of
skin idiopathic diseases for which an immune response may
be hypothesized, the role of this methodological approach
can be two-fold. On the one hand, if the immune response is
elicited by a speciﬁc pathogen, the relationship between the
pathogen and the disease may be obtained and the antigens
(molecularmimicry)concurringtothediseasemanifestation
may be identiﬁed if WB analysis is carried out using patients’
serum probed against the pathogen protein repertoire [97].
On the other hand, proteomics and immunoproteomics
may help the identiﬁcation of protein PTMs inducing
conformational alterations evoking immune/autoimmune
responses.Mediators of Inﬂammation 9
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